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In this study we have compared two different types of therapies i.e. herbal and allopathic system of 
therapies for Depression and studied them from the social perspectives. The Hypericum perforatum is 
compared with Fluoxetine [HCL] in terms of cost-utility and financial savings thereby evaluating its 
influence on annual expenditure of depressive patients that were randomly selected from 178 union 
councils of the city of Karachi, Pakistan. For both system of therapies a total of 356 patients were selected 
by stratified random sampling. Taking frequency of depression as ‘1’ annually with discount rate at 
3% for calculating the burden-of-illness in terms of disability-adjusted-life-years. The cost-utility and 
the budget-impact assessments were carried out to assess incremental-cost-effectiveness-ratio, and the 
budget-impact-per-onset as well as budget-impact-per-year values. In comparison with the Fluoxetine 
therapy, the Hypericum perforatum was found to relieve symptoms in 21.47% less cost; owing 29.23% 
less disability-adjusted-life-years and 21.45% less budget-impact-per-onset as well as budget-impact-per-
year. The annual mean incremental-cost-effectiveness-ratio was found to be at 36.95±270.74 (less than 
GDP per capita threshold of Rs. 38,173.02). Hypericum perforatum provide the optimal utility with less 
impact on budget of a patient in comparison with the treatment of symptoms of depression with Fluoxetine. 
Keywords: Hypericum perforatum. Fluoxetine. Burden of illness. Disability-Adjusted-Life-Years. 
Incremental-Cost-Effectiveness-Ratio.
INTRODUCTION
Depression has been identified as one of the 
major illnesses, which can curtail the quality of life 
along with the potential to aggravate hysteria in the 
day-to-day life. This could lead to suicide attempts that 
is prevailing these days; therefore, is becoming one of 
the apprehension of mortality in depression (Supartini, 
Oishi, Yagi, 2017). According to WHO depression is 
a psychological disorder that originates from various 
unspecified reasons. With a prevalence of 28.2% in 
young population (Oyekcin, Sahim, Aldemir, 2017) and 
with an annual rise to 113%, this psychological condition 
has been affecting 4.7% of today’s world population 
(Xu et al., 2017; Wu et al., 2017). Depression is generally 
characterized as the cerebral impairment categorized by 
the absence of a positive demeanor. This represents a 
clear loss of the presence of enthusiasm and charisma for 
personal belongings, daily life activities as well as social 
participation and person becomes introvert. Depression 
is strongly associated with indications that represents 
susceptibility to mourning, peevishness and impatience, 
frequent withdrawals, and aggravation of a very unusual 
feelings (Wu et al., 2017), particularly the presence of 
feelings of inferiority and a state of mind for guiltiness 
(Zhang et al., 2016; Supartini, Oishi, Yagi, 2017). 
There is loss of libido and the prostration along with the 
diminished body movements and noticeable nervousness 
is more recurrent than general anxiety in depression. 
During the phase of depression, insomnia as well as 
anorexia has been seen, with very few exceptions. There 
are also signs of lack of self-confidence, worthlessness, 
emotional state of powerlessness, and merited sentence 
in the form of delusion or hallucinations and efforts for 
harming oneself or any kind of suicide (Supartini, Oishi, 
Yagi, 2017). The incident of suicide linked to depression 
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includes a form of suicide, ‘hara-kiri’, however, it is 
not the only type of suicide that has been reported in 
depression (Cheung, Merry, Sundram, 2018). Even some 
studies suggest that the trivial activities like suicide 
are not in particularly linked with depression (Cheung, 
Merry, Sundram, 2018). 
Numerous plants have been reported to have such 
phytochemicals that exhibit therapeutic significance 
as an antidepressant (Saki, Bahmani, Rafieian-Kopaei, 
2014). Among them, one of the most important plants is 
Hypericum perforatum (Bukhari, Dar, 2013; Chrea et al., 
2014; Husain et al., 2011; Russo et al., 2014; Saki, 
Bahmani, Rafieian-Kopaei, 2014; Sarris, 2013; Solomon, 
Adams, Graves, 2013; Tian et al., 2014). Under various 
brand names, the herbal medicine Hypericum perforatum 
and an allopathic medicine Fluoxetine [HCl] 20mg 
(Floxac® 20mg Tablets) – a product by The Schazoo 
Laboratories (Pakistan), are utilized by patients across the 
globe (Wong, Perry, Bymaster, 2005). Although, there is 
evidence of several published pharmacoeconomics studies 
for allopathic medicines throughout the research world, yet 
there is lack of such research studies on herbal medicines 
(Huebner et al., 2017) especially in the selected region of 
the city of Karachi, Pakistan.
Previously, various studies were conducted for 
determining epidemiology of depression and the 
pharmacoeconomic benefits associated with the involved 
therapies. For example, with respect to prevalence of 
depression in citizens of the United States of America, 
each one in twelve citizens was found affected by it 
(Adkins et al., 2012). As stated by the World Health 
Organization, at the end of the year 2020, the depression 
would be the next to major causes of Disability Adjusted 
Life Years (DALYs) expected to be misplaced globally 
(Al-Qadhi et al., 2014). 
In Pakistan, from the year 1957 until 2016, due to 
the changes in consumer price index, the dynamics of 
the inflation rate averaged at 7.86% (Pakistan Inflation 
Rate, 2017). The requirement for national savings is now 
on the top priority list for Pakistan due to the inflation. 
Therefore, with respect to the treatment of depression, 
there was a need to assess two dissimilar therapies from 
the social perspective. For this, the estimation of cost per 
DALY and analysis of budget impact of therapies was 
due for the treatment of depression, i.e. the Hypericum 
perforatum (St. John’s Wort) with Fluoxetine [HCL] 
(Floxac® 20mg Tablets) in terms of the cost utility, the 
financial savings and reducing the load of depression 
with the minimum influence on annual budget of a patient 
in population of the 178 union councils of the city of 
Karachi, Pakistan.
MATERIAL AND METHODS
The herb ‘Hypericum perforatum’ was utilized as a 
sample while the allopathic medicine Fluoxetine [HCL] 
20 mg (Floxac® 20mg Tablets) was selected as a control in 
the study. The ‘Hypericum perforatum’ was used as an oral 
infusion, i.e. in 1 cup; 200mg of ‘Hypericum perforatum’ 
once a day.
Approval of study by ethical review committee
The study was started after an approval of the 
research project from Ethical Review Committee, 
Faculty of Pharmacy and Pharmaceutical Sciences, 
University of Karachi (Project Approval Protocol, dated: 
September 18, 2012, ref. no. 0671/Pharm./10(28)), for 
data collection of depressed patients. This data collection 
was confined to the physiological, medical or clinical 
information, and was constrained for collection of any 
human biological materials. The methodology of the study 
was developed in the light of the good research practices 
of Pharmacoeconomics as provided by the International 
Society of Pharmacoeconomics and Outcome Research 
(ISPOR) (Eddy et al., 2012). The methods were validated 
(Eddy et al., 2012) and replicated for the other two studies 
of the same series of research, i.e. for common cold and 
trauma in the 178 union councils of the city of Karachi.
Setting and sample
The required sample size needed for this study was 
calculated by using the following equation (Pakpour et al., 
2011):
where: n = Sample size; z = Standard normal distribution 
(1.96); p = Estimated mean of incidence proportion 
observed for the depression in the city of Karachi (i.e. 
0.05); d = Standard error (0.05).
   (n = 73)
Instead of taking least sample size of 73 patients, a 
relatively large sample size was taken into consideration, 
i.e. taking one patient from each strata or union councils 
(n = 178) patients each for fluoxetine and Hypericum 
perforatum based therapies. By taking an Average Annual 
Household Income Per Person (AAHIPP) at Rs. 99,150/- 
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(Pakistan Statistical Pocket Book 2006, 2006), the 356 
patients were selected as stratified random samples from 
population of 7,755,189 (approx. 7.76 million). The 
patients were segregated by their age and the process of 
data collection was completed in accordance with the 
proportions of each group out of 11 different age groups 
(i.e. Table I: from 25-75+ years with difference of 5 years 
in between) as defined by the Pakistan Bureau of Statistics 
(Pakistan Statistical Pocket Book, 2006). Following 
formula was used for the sample size based on age groups:
Clarity of variables in the study
Study Perspective: The societal perspective was 
followed for the present study for both the fluoxetine 
and Hypericum perforatum therapies for the depression. 
Time Horizon: The data of the 356 patients sampled for 
the Fluoxetine and Hypericum perforatum therapies were 
collected for one year (i.e. from March 2015 to February 
2016). Description of decision-analytical model: A 
simple decision tree model was used as a guide within the 
specified time horizon. Uncertainty: ‘Standard deviation’ 
(SD) and ‘Standard Error of Mean’ (SEM) were used as 
the two main parameters of statistical uncertainty for the 
study (Table III). 
TABLE I - Percentage-wise division of sample size of 178 patients among age groups in depression along with the analysis of age 
and gender homogeneity between the groups
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TABLE II - Theoretical Vs actual savings with the influence of 
annual inflation accumulated over time
Year Theoretical Savings (Rs. in Billion)
Actual Savings 
(Rs. in Billion)
1st Year 46.82 46.82
2nd Year 46.82 39.46
3rd Year 46.82 33.26
4th Year 46.82 28.03
5th Year 46.82 23.62
Total 234.10 171.19
Rs.: Pakistani rupees
TABLE III - Cost, disability-adjusted life years, burden of illness, incremental cost-effectiveness ratio and budget impact assessments 
of Fluoxetine and Hypericum perforatum based therapies for depression in 178 union councils of the city of Karachi
Analysis Related Therapy Sex N Minimum Maximum Mean
Std. Error of 
Mean Std. Deviation Variance
COI (in Rs.)
COIF 178 56,662.00 138,503.00 96,147.17 1,323.67 17,659.92 311,872,663.46
Male 100 56,662.00 138,312.00 94,733.34 1,775.56 17,755.58 315,260,737.72
Female 78 65,149.00 138,503.00 97,959.78 1,979.52 17,482.64 305,642,636.35
COIH 178 45,903.00 100,553.00 75,501.19 914.74 12,204.15 148,941,386.36
Male 85 53,601.00 98,321.00 75,262.28 1,168.06 10,768.95 115,970,178.01
Female 93 45,903.00 100,553.00 75,719.55 1,393.39 13,437.39 180,563,528.51
DALY (in 
Years)
DALYF 178 1,893.64 3,821.57 2,805.15 34.11 455.05 207,070.06
Male 100 1,893.64 3,805.16 2,794.18 45.11 451.14 203,529.12
Female 78 1,965.89 3,821.57 2,819.21 52.37 462.55 213,955.31
DALYH 178 1,561.49 3,515.60 2,368.86 30.56 407.71 166,230.34
Male 85 1,600.24 3,485.66 2,371.99 44.29 408.34 166,739.18
Female 93 1,561.49 3,515.60 2,365.99 42.45 409.34 167,555.19
COI/DALY 
(in Rs. per 
Year)
COIF/DALYF 178 17.45 62.92 35.23 0.67 8.99 80.77
Male 100 17.45 57.75 34.83 0.88 8.83 78.06
Female 78 20.66 62.92 35.73 1.04 9.21 84.84
COIH/DALYH 178 16.50 59.31 32.80 0.58 7.79 60.76
Male 85 16.50 57.57 32.56 0.75 6.92 47.96





DALYF/1000 178 18,428.90 63,923.40 36,474.07 809.81 10,804.20 116,730,693.58
Male 100 18,428.90 61,885.95 36,422.15 1,076.71 10,767.11 115,930,753.01
Female 78 18,723.14 63,923.40 36,540.64 1,236.55 10,920.95 119,267,181.03
DALYH/1000 178 30,431.83 222,815.24 89,753.35 3,004.16 40,080.56 1,606,450,989.98
Male 85 30,431.83 222,815.24 89,188.20 4,306.78 39,706.56 1,576,610,705.46




BIPOF or BIPYF 178 57.15 139.69 96.97 1.34 17.81 317.24
Male 100 57.15 139.50 95.55 1.79 17.91 320.68
Female 78 65.71 139.69 98.80 2.00 17.63 310.91
BIPOH or BIPYH 178 46.30 101.42 76.15 0.92 12.31 151.51
Male 85 54.06 99.16 75.91 1.18 10.86 117.97
Female 93 46.30 101.42 76.37 1.41 13.55 183.68
ICER 178 (2,428.55) 1,037.71 36.95 20.29 270.74 73,300.02
Valid N (listwise) 178
Rs.: Pakistani Rupees; COI: Cost of illness; DALY: Disability adjusted life years; COI/DALY: Cost per disability adjusted life year; BIPO: Budget impact per 
onset; BIPY: Budget impact per year; ICER: Incremental cost effectiveness ratio
Survey instrument and data collection
For obtaining the maximum data input from 356 
patients selected in the research study, a bilingual layered 
style interviews, questionnaires and opinion surveys 
(Groves et al., 2011; Dillman, Smyth, Christian, 2014) 
were devised, which consists of a blend of open and 
closed-ended questions. The interviews were rarely used 
in situations where respondents were unable to feedback 
to the questionnaires due to diversified reasons. The 
questionnaires and opinion surveys were available to 
the respondents in the form of choices between paper-
based as well as an online (survey with Limesurvey™ 
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and surveymonkey.com). Surveys were the only mode 
of data collection that were more convenient to gather 
information. They were found relatively cheap and 
respondent-friendly than the interviews as surveys can be 
completed and submitted with patient’s own ease and will.
Utilization of database for data collection and 
preliminary calculations
Since there were no database available for the herbal 
and allopathic therapies chosen in relevance with the 
scope of the study, therefore, the fresh data were collected 
from 356 patients from 178 union councils in the city of 
Karachi. The information gathered from either interviews, 
questionnaires or opinion surveys were distributed into 
two categories. The first category of data deal with 
epidemiological data including incidences as well as 
old cases to calculate the prevalence of depression. The 
second category of data deal with the addresses of patients 
including their towns and union councils, their genders and 
age, the monthly household income, fees of physicians/
herbal practitioners, the cost of medicines and transport, 
the loss of income and the loss due to pain experienced in 
the condition of depression. All the data input was used 
to calculate: the disability adjusted life years (DALY), an 
incremental cost effectiveness ratio (ICER), budget impact 
per onset (BIPO), budget impact per onset differences 
(BIPOD), budget impact per year (BIPY), budget impact 
per year differences (BIPYD) and the actual savings. 
Data analysis
The data were gathered gradually and calculated into 
meaningful and required pharmacoeconomic evaluations 
(cost utility analysis and the budget impact analysis) via 
software, i.e. with Microsoft Excel 2016. The detailed 
statistical analysis was performed along with graph 
generation with the help of IBM® SPSS version 23. For 
the Cost utility analysis and Budget impact analysis 
we divided the process in different stages for better 
understanding of collected data and ease of calculations.
Cost utility analysis was carried out in four steps 
as follows:
•	 To determine ‘prevalence’ of depression in 178 
union councils of the city of Karachi.
•	 To calculate ‘cost utility’ (by utilizing results from 
calculations for ‘prevalence’ and the ‘cost of illness’ 
with exchange rate of Rs. 104/- per USD):
o The ‘disability adjusted life years (DALYs)’.
o The ‘disability adjusted life years (DALYs) per 
1000 people’.
o The ‘cost of illness per disability adjusted life 
year’ (COI per DALY).
o The ‘incremental cost effectiveness ratios’ by 
computing the results from calculations of ‘cost 
of illness’ and the ‘disability adjusted life years 
(DALYs).
The budget impact analysis was carried out in five 
steps:
•	 First step was to utilize the results of ‘cost of ill-
ness’ and the ‘average annual household income 
per person (AAHIPP)’ in the calculation of ‘budget 
impact per onset (BIPO)’ for each patient receiving 
fluoxetine or Hypericum perforatum treatments.
•	 The second step was to determine the ‘budget impact 
per onset difference (BIPOD)’ between BIPOs.
•	 The third step was to utilize the results of ‘cost of 
illness’ and the ‘average annual household income 
per person (AAHIPP)’ in the calculation of ‘budget 
impact per year (BIPY)’ for each patient.
•	 The fourth step was to calculate the ‘budget impact 
per year difference (BIPYD)’ between BIPYs.
•	 The fifth step was to determine and compare the 
‘actual savings’ with the ‘theoretical savings’ in 
context of the societal perspective.
The overall perspective of data analysis was to 
analyze ‘what if’ all the patients in the city of Karachi 
were treated with only one of the therapies to determine 
pharmacoeconomically best therapy for depression 
in the society. For the cost utility analysis and budget 
impact analysis we divided the process in different stages 
for better understanding of collected data and ease of 
calculations.
Prevalence
Prevalence was calculated by summing up new 
cases for reported depression and the old cases existed 
in Karachi (Sullivan et al., 2014). The data for the total 
population were calculated from the Pakistan Bureau of 
Statistics (Pakistan Statistical Pocket Book, 2006). While 
incidences and data of old cases were gathered from clinics 
and hospitals exist in all 178 union councils of Karachi. 
Prevalence was calculated by:
Prevalence = [Incidence + Old Cases]
where, Incidence = No. of new cases reported within time 
of study; Old Cases = No. of old cases reported within 
time of study.
Cost of Illness
Cost of illness was calculated for its utilization 
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for USD per DALY and in calculations for incremental 
cost effectiveness ratio (ICER). The cost of illness was 
calculated by summing up direct and indirect costs 
(Sullivan et al., 2014):
Cost of Illness = [Direct Costs + Indirect Costs]
where, Direct Costs = Fee of Practitioner + Costs of 
Medicine + Transport Costs; Indirect Costs = Loss of 
Income + Loss due to Pain
Disability Adjusted Life Years (DALYs)
For each patient in either of the Fluoxetine and 
Hypericum perforatum treatments, the disability-adjusted 
life years (DALYs) were calculated, by summing up the 
years of lifetime lost (YLL) due to the premature death and 
the years that are misplaced (YLD) due to the disability. 
The discount rate of 3% was considered in the study 
utilizing the following formulas (Donev et al., 2010):
DALY = YLL + YLD
where,
therefore,
where, N = number of deaths; r = discount rate (constant 
rate of 0.03 in clinical calculations); e = natural logarithm 
(constant value of approx. 2.71828); LDT = standard life 
expectancy at age of death in years; P = prevalence 
of depression; DW= disability weight i.e. 0.294 for 
depression (Haagsma et al., 2015); LDB = average duration 
of the case until remission or death (years).
The DALY per 1000 people was calculated by 
following formula:
The COI per DALY was calculated with the help of 
input cost of illness:
Incremental Cost Effectiveness Ratio (ICER)
The incremental cost-effectiveness ratio (ICER) was 
calculated as part of cost-utility assessment, computing 
the costs and the disability adjusted life years (DALYs) of 
both Fluoxetine and the Hypericum perforatum therapies. 
A formula employed (Muennig, Bounthavong, 2016) to 
calculate the incremental cost-effectiveness ratio (ICER) 
was:
In the year 2016, the gross domestic product (GDP) 
per capita income for Pakistan was Rs. 152,692.07/- 
(World Bank, 2016) and with reference to it, the GDP 
per capita threshold (that was supposed to be 4 times less 
than the GDP per capita) was Rs. 38,173.02/-. In order to 
be identified as the preferred and economically beneficial 
therapy, the cost per disability-adjusted life year for either 
of the therapies elaborated in the treatment of depression 
must remain under the GDP per capita threshold (WHO, 
2016).
Budget impact per onset (BIPO)
BIPOs, both for allopathic and herbal therapies of 
depression were calculated by the following formula:
For the allopathic therapy with Fluoxetine:
For the herbal therapy with Hypericum perforatum:
where, BIPOF = budget impact per onset for the Fluoxetine; 
BIPOH = budget impact per onset for the Hypericum 
perforatum; COIF = cost of illness with the fluoxetine; 
COIH = cost of illness with the Hypericum perforatum; 
AAHIPP = average annual household income per person.
Budget impact per onset difference (BIPOD)
For budget impact per onset difference, again the 
fluoxetine therapy was given a benefit of doubt and 
therefore, the budget impact per onset in the Hypericum 
perforatum therapy (BIPOH) was subtracted from the 
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budget impact per onset in Fluoxetine therapy (BIPOF). 
The budget impacts per onset difference (BIPOD) between 
BIPO of allopathic and herbal therapies of depression (i.e. 
BIPOF and BIPOH) were calculated by following formula:
BIPOD = BIPOF – BIPOH
or
Budget impact per year (BIPY):
The budget impacts per year (BIPY) were calculated 
by the following formula:
For the allopathic therapy with Fluoxetine:
For the herbal therapy with Hypericum perforatum:
Budget impact per year difference (BIPYD)
Like the budget impact per onset difference, the 
budget impact per year in the Hypericum perforatum 
therapy (BIPYH) was subtracted from the budget impact 
per year in the Fluoxetine therapy (BIPYF). To calculate 
the budget impact per year difference (BIPYD) following 
formula was used:
BIPYD = BIPYF – BIPYH
OR
where, BIPYF = budget impact per year for the Fluoxetine 
therapy; BIPYH = budget impact per year for the 
Hypericum perforatum therapy; f = approx. yearly 
frequency of the depression.
Projected actual savings
Projected actual savings were calculated on basis of 
choice and the use of preferred treatment. To differentiate 
actual savings scenario from the theoretical/ideal saving 
scenario (where the inflation does not take part), the actual 
savings for current year with inflation were calculated by:
Projected actual savings for a year = [Savinga of Last 
Year × {1 – (2 × 0.0786)}]
Extrapolation of the internal and external validity 
of the study findings
Internal Validity: The univariate analysis of variance 
(One-way ANOVA) was performed, individually taking 
sex, age group, age, cost of illness, DALYs and BIPO 
as independent variables versus DALYs, DALYs/1000, 
BIPO, and ICER as dependent variable to find out the 
potential relationship among independent and dependent 
variables via identification of level of significance to 
validate internally the authenticity of the study findings. 
External Validity: The same methodology was 
replicated for the dissimilar conditions such as common 
cold and trauma among a population in the city of 
Karachi, for retrospective cost-utility and budget impact 
assessments to carry out the external validity of the study 
findings.
RESULTS
The results for the cost utility and the budget impact 
analysis were:
Prevalence of depression
The prevalence of depression in selected population 
of Karachi was found to be at 2,268,127 (approx. 2.27 
million) people (Table IV).
Costs of Illness
The annual cost of illness in Fluoxetine based 
allopathic therapy (Table IV) was estimated at Rs. 
218.07/- billion (USD 2 billion and 96.83/- million) 
while for Hypericum perforatum based therapy at Rs. 
171.25/- billion (USD 1 billion and 646.63/- million). 
There was a clear difference of Rs. 46.82/- billion (USD 
450.19/- million) between the two therapies if projected 
over the patients of depression in the city of Karachi.
Cost utility analysis
Disability adjusted life years (DALYs)
The mean disability adjusted life years (DALYs) 
in cases of therapies with Fluoxetine and Hypericum 
perforatum were found to be 499,020.37 years and 
353,150.95 years respectively, with a difference of 
145,869.42 years (i.e. 29.23%).
S. M. Ahmad, D. Masroor, I. Azhar, N. Ahmed
Braz. J. Pharm. Sci. 2019;55:e17210Page 8 / 12
Disability adjusted life years (DALYs) per 1000 
people
The disability adjusted life years (DALYs) per 
1000 people were 6,362,436.45 years and 5,372,875.33 
years in case of treatment with fluoxetine and Hypericum 
perforatum respectively, with a difference of 989,561.13 
years. Considering the selected union councils population, 
disability adjusted life years (DALYs) per 1000 people 
were 36,474.07 years and 89,753.35 years for fluoxetine 
and Hypericum perforatum, with a difference of 53279.28 
years (Figure 2B).
COI per DALY
The COI per DALY was found to be at Rs. 35.23/- 
and Rs. 32.80/- in Fluoxetine and Hypericum perforatum 
based therapies, with difference of Rs. 2.43/-.
Incremental cost-effectiveness ratio (ICER)
Mean ICER in Fluoxetine and Hypericum perforatum 
therapies (Table III) was observed to be at 36.95 per patient 
per onset of depression with SD of ±270.74 in the overall 
population. The ICER percentile 25th and percentile 75th 
were estimated at -0.03 and 82.28 respectively among 178 
union councils of city of Karachi. The ICER with reference 
to the prevalence of depression was found to be at 0.0003 
for city of Karachi (Table IV).
Budget impact analysis
Budget impact per onset and budget impact per year
Since, the depression is a multiple years long 
condition, the budget impact per onset (BIPO) and the 
budget impact per year (BIPY) based on average annual 
household income were both the same. It was estimated 
at 96.97% and 76.15% for fluoxetine and Hypericum 
perforatum therapies (Figure 3A). During the study, a 
direct relationship of COI was identified with BIPO and 
BIPY.
Budget impact per onset difference and budget impact 
per year difference
The budget impact per onset difference (BIPOD) 
and the budget impact per year difference (BIPYD) were 
both estimated at 20.82%. 
Actual savings
An annual savings of Rs.46.82/- billion (USD 
450.19/- million) was calculated as a difference when using 
Hypericum perforatum as a mode of treatment (Figure 
3B). However, the five-year savings of Rs.171.19/- billion 
(USD 1 billion and 646.06/- million) was found due to the 
dual impact of inflation rate in Pakistan (Table II)
Analysis of age and gender homogeneity
Although five (5) age groups, i.e. ‘25 – 29 yrs.’, 
‘40 – 44 yrs.’, ‘50 – 54 yrs.’, ‘55 – 59 yrs.’ and ‘70 – 74 yrs.’ 
(Table I; Figure 1) were found with more males than 
females; the four (4) age groups, i.e. ‘30 – 34 yrs.’, 
‘35 – 39 yrs.’, ‘60 – 64 yrs.’, and ‘65 – 69 yrs.’ were found 
with more females than males. While only two (2) age 
groups, i.e. ‘45 – 49 yrs.’ and ‘75 yrs. and up’ were found 
with equal genders. Therefore, in overall 356 patients 
for both Fluoxetine and Hypericum perforatum based 
therapies, the number of males were found higher, i.e. 
184 males than 172 females.
Internal and external validation
The univariate analysis of variance (One-way 
ANOVA) for the variables pointed out a very strong 
relationship between the cost of illness and the budget 
impact per onset by having significance level < 0.05. 
No other potential relationship was identified among the 
variables, i.e. pointing towards the authenticity of the 
results of the study. The extrapolation of results of the 
study was expanded to two other retrospective studies on 
the same population of the city of Karachi for conditions 
of common cold and trauma revealing the preferences 
TABLE IV - Cost, burden of illness and budget impact assessment of fluoxetine and Hypericum perforatum based therapies for the 
depression in the city of Karachi
Prevalence
Fluoxetine Based Therapy Hypericum perforatum Based Therapy






















2,268,127 218.07 499020.37 0.0004 6,362,436.45 96.97% 96.97% 171.25 353150.95 0.0005 5,372,875.33 76.15% 76.15% 20.82% 20.82% 0.0003
UC: Union Council; Pt.: Patient; Rs.: Pakistani Rupees; COI: Cost of illness; DALY: Disability adjusted life years; COI/DALY: Cost per disability adjusted life year; BIPO: Budget 
impact per onset; BIPY: Budget impact per year; BIPOD: Budget impact per onset difference; BIPYD: Budget impact per year difference; ICER: Incremental cost effectiveness ratio
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of herbal therapies over allopathic therapies in terms of 
providing more utility with less impact on the household 
budgets of patients.
DISCUSSION
It is well understood that in the cost utility analysis, 
the cost per disability-adjusted life years for either of 
the therapies calculated in terms of ICER (Muennig, 
Bounthavong, 2016) must remain under the GDP per 
capita threshold (WHO, 2016). As the study concluded 
that the ICER was 36.95 per patient per onset of depression 
with reference to the GDP per capita income for Pakistan 
(i.e. Rs. 152,692.07/- (World Bank, 2016), the ICER 
was found well below the GDP per capita threshold of 
Rs. 38,173.02/- (WHO, 2016).
Hypericum perforatum was found to have more 
utility than Fluoxetine because of lesser disability adjusted 
life years (i.e. having 145,869.42 years lesser; Figure 2A). 
Also, with reference to the comparative mean cost per 
DALY, it has the lower cost with a percentage difference 
of 6.90, i.e. Rs. 2.43/-.
The budget impact analysis in the current study 
established the utility value of Hypericum perforatum 
as compare with the Fluoxetine based therapy. The 
budget impact per onset difference of 20.82% (or 
Rs. 46.82 billion, i.e. USD 450.19/- million) was found 
less impactful and could be hypothetically saved on a 
societal level, only if the patients with depression would 
get oral infusion of Hypericum perforatum as a medicine. 
This difference could be theoretically projected into 
five-years savings of Rs. 234.1/- billion (USD 2 billion 
and 250.96/- million). However, in practice, an annual 
savings (Figure 3B) of Rs.46.82/- billion (USD 450.19/- 
million) would translate into five-year savings of 
Rs.171.19/- billion (USD 1 billion and 646.06/- million) 
due to the dual impact of inflation rate in Pakistan (Table 
II). This dual impact of inflation affects the supply of 
Hypericum perforatum against annual demand as well 
as on savings generated by Hypericum perforatum 
therapy. It must be noted that this value of accumulated 
savings is close to the cost incurred by the Hypericum 
perforatum therapy for the whole year in the city of 
Karachi. Therefore, the use of the Hypericum perforatum 
therapy is still beneficial in developing country like 
Pakistan where the poverty rate is very high due to the 
poor economic development and inequality in the society 
(Piazza, 2006; Fuentes-Nieva et al., 2014). 
CONCLUSION
Considering the results of cost utility and the 
budget impact analysis along with the projected actual 
accumulative savings, the utilization of Hypericum 
perforatum based herbal  therapy proved more 
pharmacoeconomically beneficial than the Fluoxetine 
based therapy for the treatment of depression in population 
of the city of Karachi. 
FIGURE 1 - Analysis of age and gender homogeneity in cost-utility and budget impact assessments of Hypericum perforatum in 
contrast with fluoxetine treatment (blue line with ● marker: Male; red line with ■ marker: Female).
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FIGURE 2 - Cost-utility assessment of Hypericum perforatum 
in contrast with fluoxetine treatment (A) COI Vs DALY – 
fluoxetine and Hypericum perforatum in UCs (● blue marker 
- fluoxetine; ▲ red marker - Hypericum perforatum); (B) DALY 
1000 Vs COI – fluoxetine and Hypericum perforatum in UCs 
(● fluoxetine; ○ Hypericum perforatum).
FIGURE 3 - Budget impact assessments of Hypericum 
perforatum in contrast with Fluoxetine treatment (A) Budget 
Impact Per Onset and Budget Impact Per Year in UCs (● BIPO 
and BIPY Fluoxetine; ○ BIPO and BIPY Hypericum perforatum; 
◊ BIPOD and BIPYD); (B) Theoretical Vs Actual Savings (Blue 
line: Theoretical Savings; Green line: Actual Savings).
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